Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Nova Mentis Life Science Corp. (C:NOVA)

Business Focus: Biotechnology & Medical Research (NEC)

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for NOVA within the last 6 months
See all filings within the past 6 months

Company News

Jul 11, 2022 08:30 ET
Nova Mentis to Present Promising Psilocybin Microdose Data at 18th NFXF International Fragile X Conference
Vancouver, British Columbia--(Newsfile Corp. - July 11, 2022) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce it will be discussing the therapeutic potential of oral microdose psilocybin for the treatment of autism spectrum disorder (ASD) and fragile X syndrome (FXS) during a poster presentation at the 18th NFXF International Fragile X Conference, taking place July 14-17, 2022 in San Diego, California.
Read full article
Jun 23, 2022 10:29 ET
CEO’s of BOXD, NEXCF, NMLSF, and SMFL Driving Innovation, and Revenue Growth Opportunities with Innovation in Web 3.0, E-Commerce, Baby Nutrition and Psychedelics-based Therapies
Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEO’s of: Boxed, Inc. (NYSE: BOXD), NexTech AR Solutions (OTC: NEXCF) (CSE: NTAR), Smart for Life (NASDAQ: SMFL),...
Read full article
See more news stories

Valuation Ratios

Price to Sales - TTM
Price to Book - most recent quarter
Price to Cash Flow per share - TTM
Price to Free Cash Flow per share - TTM
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Jul 15, 2022159,197117,321
Jun 30, 202241,87638,819
Jun 15, 20223,057-6,180
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

Nova Mentis Life Science Corp. is a Canada-based biotechnology company. The Company is engaged in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. The Company operates in two segments: development of cannabis products and research and development of psilocybin in Canada through the Company's subsidiaries, Nova Mentis Biotech Corp. and Pilz Bioscience Corp. Nova Mentis Biotech Corp. and Pilz Bioscience Corp. is engaged in psilocybin research and development. Nova Mentis Biotech Corp. is engaged in the development of psilocybin-based therapeutics and diagnostics for neuroinflammatory disorders. It is focused indications are obesity, diabetes, liver disease. Pilz Bioscience Corp. (Pilz) is a biotechnology company developing medicinal psychedelics for neuroinflammatory conditions with a cognitive component and high unmet therapeutic needs. The initial focus is on Autism Spectrum Disorder (ASD).

See business summary



Search (past week) for $NOVA.CA

  • No tweets found